Why the study?
Does TFCC pretreatment prevent doxorubicin-induced cardiotoxicity in preclinical models?
Population
Male rats and H9C2 cardiomyocytes
Comparison
Total flavonoids from Clinopodium chinense O… vs Doxorubicin alone and/or vehicle control
Design
Preclinical
Follow-up
2 weeks after the last DOX dose (in vivo)
Authors
Loading...
May support TFCC development for doxorubicin cardiotoxicity prevention; leaves open clinical translation pending human trials.
Does TFCC pretreatment prevent doxorubicin-induced cardiotoxicity in preclinical models?
TFCC shows potential in preventing doxorubicin-induced cardiotoxicity through modulation of apoptotic and survival signaling pathways in preclinical models.
Chen et al. (2015) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: